Division of Hematology/Oncology

Faculty

faculty photo

David L. Porter, MD

Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Blood and Marrow Transplantation, Hospital of the Univeristy of Pennsylvania
Department: Medicine

Contact information
Hematology-Oncology
3400 Civic Center Boulevard
PCAM 2 West Pavillion
Philadelphia, PA 19104
Office: 2156622862
Fax: 2156155888
Education:
B.A. (Biochemistry)
University of Rochester, 1981.
M.D. (Medicine)
Brown University, 1987.
Post-Graduate Training
Medical Intern, University Hospital, BU Med. Ctr., Boston, 1987-1988.
Junior Assistant Resident, University Hospital, Boston, 1988-1989.
Senior Assistant Resident, University Hospital, Boston, 1989-1990.
Clinical Fellow in Hematology-Oncology, Brigham and Women's Hosp., Boston, 1990-1991.
Clinical Fellow in Hematology-Oncology, Harvard Medical School, Boston, 1990-1991.
Research Fellow in Hematology-Oncology, Harvard Medical School, Boston, 1991-1993.
Research/Clinical Fellow in Hematology-Oncology, Brigham & Women's Hospital, Boston, 1991-1993.
Certifications
American Board of Internal Medicine, Certificate No. 130268, 1990.
Subspecialty in Medical Oncology American Board of Internal Medicine , 1993.
Subspecialty in Hematology American Board of Internal Medicine , 1994.
Subspecialty in Hematology American Board of Internal Medicine , 2006.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S, Schuster S , Stadtmauer E, Schuster MG.: High Rate of Invasive Fungal Infections Following Nonmyeloablative Allogeneic Transplantation, Clinical Infectious Disease. 36: 9-15, 2003.

Loren AW, Luger SM, Duffy KM, Stadtmauer E, Tsai D, Schuster S, Nasta S, Klumpp T, Orloff G, Porter D. : Alemtuzumab prevents acute graft-vs-host disease (aGVHD) in non-myeloablative stem cell transplants (NST) from unrelated donors. Proc Am Soc Clin Oncol 2003.

Buckanovich R, Porter DL.: Polycythemia Vera. Conn’s Current Therapy 55th edition. Rakel RE and Bope ET (eds.). Page: 503-506, 2003.

Loren AW, Tsai DE, Porter DL, Stadtmauer EA.: Posttransplant lymphoproliferative disorder: A review. Bone Marrow Transplant 31: 145-155, 2003.

Porter DL, Stadtmauer EA, Lazarus H. : "GVHD": Graft-vs-Host Disease or Graft-vs-Hodgkin's Disease? An Old Acronym with New Meaning. Bone Marrow Transplant 31: 739-746, 2003.

Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski W, Barrett AJ, Porter DL Giralt S, Horowitz M, Leis J, Johnson MP, Collins RH.: Chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies following allogeneic stem cell transplantation. J Clin Oncol 20: 405-412, 2002.

Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA.: Gemtuzumab Ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant 30: 23-28, 2002.

French LE, Alcindor R, Shapiro M, Margolis DJ, Porter D, Leonard DGB, Rook AH, Foss F.: Identification of amplified clonal T cell populations in the blood of patients with chronic graft versus host disease: positive correlation with response to photopheresis. Bone Marrow Transplant 30: 509-515, 2002.

Bilenker JH, Demers R, Porter DL, Wasserstein AG., MD, Maniker, S.: Recombinant Human Erythropoietin Usage in a Large Academic Medical Center. American Journal of Managed Care 8: 742-747, 2002.

back to top
Last updated: 01/26/2012
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter